Express Pharma

SEPTEMBER 4, 2024

Whilst most cases are mild and resolve within a few weeks, some people – particularly children, pregnant women, and those with suppressed immune systems – may endure more severe disease, which can be fatal. The SPRP covers a six-month period from September 2024 to February 2025.

Vaccines 104

Vaccines Immunization Immunity 104

Pharmaceutical Business Review

SEPTEMBER 2, 2024

The Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) [NVX-CoV2705] is now authorised for active immunisation against Covid-19. Following the EUA, the vaccine is also recommended by the US Centers for Disease Control and Prevention (CDC). Our updated vaccine targets JN.1, 1.” “Our updated vaccine targets JN.1,

Vaccines 59

Vaccines Adverse Reactions Immunization Immunity 59

Pharmacy Times

MARCH 23, 2025

Goad, PharmD, MPH, discusses the latest RSV vaccination guidelines and recommendations for 2025, highlighting vaccine options, target populations, timing considerations, evolving CDC policies, and the role of pharmacists in immunization efforts.

Vaccines 29

Vaccines Immunization Immunity 29

Express Pharma

MARCH 3, 2025

Zydus Lifesciences announced its focus on the development of a combination vaccine against shigellosis and typhoid. Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine.

Vaccines 52

Vaccines Immunization Immunity 52

Big Molecule Watch

FEBRUARY 17, 2025

On February 5, 2025 Valneva SE (Valneva) announced that the United Kingdoms Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization for Valnevas chikungunya vaccine, IXCHIQ. The post UKs MHRA Grants Marketing Authorization for Chikungunya Vaccine appeared first on Big Molecule Watch.

Vaccines 45

Vaccines Immunization Immunity Labelling 45

pharmaphorum

JANUARY 10, 2022

The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease. Pfizer already has a head start on competitors in the field, having achieved the first US FDA approval for an mRNA vaccine, alongside BioNTech.

Vaccines 111

Vaccines Immunization Immunity 111

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Until 2025, the companies will equally share the research and intellectual property licensing expenses under the partnership.

Vaccines 52

Vaccines Immunization Immunity 52

pharmaphorum

JUNE 15, 2022

Cytokines have long been investigated for their potential as cancer treatments – selectively stimulate tumour-fighting immune cells – with varying levels of success. Trutino’s lead in-house asset is in early-stage development and scheduled to start clinical testing in solid tumours in 2025.

Immunization 98

Immunization Immunity Vaccines 98

Pharmaceutical Technology

JUNE 20, 2023

The proposed institute will focus on vaccine research, public health research, therapeutics, genomics, diagnostics, clinical trials and data. Demolition of the existing buildings on the site will commence next year, and construction work on the new building will begin in 2025.

Immunization 52

Immunization Immunity Vaccines 52

Pharmaceutical Technology

JULY 29, 2022

Pfizer (New York, New York) and Moderna’s (Cambridge, Massachusetts) Omicron-specific Covid-19 vaccines are in late-stage development, have demonstrated good efficacy against the variant and will likely be available to the public later this year to provide an additional booster and increase demand for injectable manufacturing.

Vaccines 52

Vaccines Packaging Immunization Immunity 52

pharmaphorum

OCTOBER 12, 2022

Del Bourgo highlights that genomic treatments work in a similar way to mRNA, which has been used in COVID-19 vaccines. Similar to how we injected mRNA into people to trigger an immune response and train their immune system against COVID-19, genomic medicine repairs cellular or molecular mechanisms that are dysfunctional and cause disease.”.

Drug Development 105

Drug Development Immunization Immunity Vaccines 105

PharmaShots

JUNE 1, 2023

PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. We reported at ESMO-IO the analysis of immune response of the first 3 cohorts of patients.

Immunization 40

Immunization Immunity Vaccines Health and Personal Care Stores 40

Express Pharma

JULY 3, 2023

Many millions of people are vaccinated against COVID-19, thanks to a messenger RNA (mRNA) encapsulated within a lipid nanoparticle. The biosimilar market in India is estimated to grow at 22 per cent CAGR to become $12 billion by 2025.

Biosimilars 95

Biosimilars Drug Development Generic Medicine Diabetes 95

pharmaphorum

JANUARY 13, 2023

Everyone agrees that cell and gene therapies are poised for an explosion, with far more drugs in the pipeline than are currently approved, and the FDA predicts it will clear 10 to 20 per year by 2025. These therapies have incredible potential to fight cancer and other diseases using the patient’s own immune system.

Drug Pricing 98

Drug Pricing Immunity Immunization Vaccines 98

Pharmaceutical Technology

APRIL 24, 2023

Demand for biologics, including vaccines, is at an all-time high, in the post-Covid era. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures. The approval of the mRNA Covid-19 vaccine, which is a biologic, has thrust the modality even further into the spotlight.

Vaccines 52

Vaccines Compounding Communication Immunity 52

PharmaShots

MAY 23, 2023

Propelled by constant innovatory winds, the Cell and Gene therapy market is anticipated to grow by 20 percent year-over-year through 2025. It has triple mutation within the viral genome that causes augmented and selective replication in cancer cells and enhances induction of antitumor immune response.

Diabetes 58

Diabetes Immunity Immunization Pharmaceutical Companies 58

STAT

MARCH 21, 2025

In 2000, after decades of hard work and widespread vaccination campaigns, public health officials declared measles eliminated in the U.S. Fueled by growing mistrust in vaccine science and years of small but meaningful declines in routine childhood vaccinations, measles has made a troubling comeback. Read the rest…

Vaccines 357

Vaccines Documentation Immunization Immunity 357

European Pharmaceutical Review

FEBRUARY 3, 2025

EMAs human medicines committee (CHMP) recommended eight medicines for EU marketing authorisation at its January 2025 meeting. New vaccine Vimkunya (chikungunya vaccine (recombinant, adsorbed)) was also recommended for individuals 12 years old and adults to prevent disease caused by the Chikungunya virus.

Vaccines 52

Vaccines Generic Medicine Chemotherapy Biosimilars 52

Safe Biologics

MARCH 10, 2025

However, the nominee has also received criticism about his views on other health policies such as vaccine safety. Kennedy has insisted that he is not “anti-vaccine” and has pledged not to ban vaccines under Trump. PBM Reform: Could 2025 Finally See a Long-Awaited Overhaul? Read the FTC Report here.

Biosimilars 130

Biosimilars Independent Pharmacies Drug Pricing Vaccines 130